BS_SDZY6RZ3
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 36.136662286465175
- age_years
- 5.296
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.535
- ANDROGEN_RESPONSE+0.444
- INTERFERON_ALPHA_RESPONSE+0.401
- CHOLESTEROL_HOMEOSTASIS+0.374
- INTERFERON_GAMMA_RESPONSE+0.364
- IL6_JAK_STAT3_SIGNALING+0.342
- ADIPOGENESIS+0.338
- INFLAMMATORY_RESPONSE+0.333
- COMPLEMENT+0.325
- MTORC1_SIGNALING+0.323
Top 10 suppressed
- G2M_CHECKPOINT-0.396
- E2F_TARGETS-0.391
- MYC_TARGETS_V2-0.364
- MYC_TARGETS_V1-0.247
- WNT_BETA_CATENIN_SIGNALING-0.186
- DNA_REPAIR-0.164
- MITOTIC_SPINDLE-0.160
- SPERMATOGENESIS-0.093
- KRAS_SIGNALING_DN-0.042
- UV_RESPONSE_UP+0.043
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_X16PENSA | pilocytic astrocytoma | — | 0.936 |
| 2 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.935 |
| 3 | BS_6N3AFF66 | pilocytic astrocytoma | — | 0.934 |
| 4 | BS_Q79NP5YY | pilocytic astrocytoma | — | 0.932 |
| 5 | BS_VW85Q4XJ | low-grade glioma | — | 0.928 |
| 6 | BS_BKQZ550R | pilocytic astrocytoma | — | 0.926 |
| 7 | BS_42Y3YANN | pilocytic astrocytoma | — | 0.923 |
| 8 | BS_49852ZBH | pilocytic astrocytoma | — | 0.917 |
| 9 | BS_FJWZ3M7V | low-grade glioma | — | 0.915 |
| 10 | BS_HV8PFRBR | pilocytic astrocytoma | — | 0.911 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.535 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.444 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.401 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.374 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.364 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.342 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.338 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.333 | Idelalisib | — uncovered |
| COMPLEMENT | 0.325 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.323 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.321 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.321 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.318 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.307 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.301 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.292 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.285 | Inavolisib | — uncovered |
| HYPOXIA | 0.283 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.268 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.266 | Idelalisib | — uncovered |